Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jaap Fransen

Showing results (51-60 of 108) with videos related to

Pageof 11
Sort By:
Pharmacogenomics|January 11, 2019
Validation of a clinical pharmacogenetic model to predict methotrexate nonresponse in rheumatoid arthritis patientsFrank Eektimmerman, Cornelia F Allaart, Johanna M Hazes, et al.
Annals of the Rheumatic Diseases|November 14, 2009
Limited validity of the American College of Rheumatology criteria for classifying patients with gout in primary careHein J E M Janssens, Mathijs Janssen, Eloy H van de Lisdonk, et al.
Clinical and Experimental Rheumatology|August 6, 2013
A comparison of the measurement properties and estimation of minimal important differences of the EQ-5D and SF-6D utility measures in patients with systemic sclerosisLinda Kwakkenbos, Jaap Fransen, Madelon C Vonk, et al.
The Journal of Rheumatology|March 3, 2010
Multiplex screening of 22 single-nucleotide polymorphisms in 7 Toll-like receptors: an association study in rheumatoid arthritisChristian Enevold, Timothy R D Radstake, Marieke J H Coenen, et al.
Rheumatology (Oxford, England)|August 14, 2016
Survival and organ involvement in patients with limited cutaneous systemic sclerosis and anti-topoisomerase-I antibodies: determined by skin subtype or auto-antibody subtype? A long-term follow-up studyPim Kranenburg, Wieneke M T van den Hombergh, Hanneke K A Knaapen-Hans, et al.
Pharmacogenomics|July 31, 2012
Clinical pharmacogenetic model to predict response of MTX monotherapy in patients with established rheumatoid arthritis after DMARD failureJaap Fransen, Wouter M Kooloos, Judith A M Wessels, et al.
Arthritis Research & Therapy|February 18, 2010
Functional consequences of DECTIN-1 early stop codon polymorphism Y238X in rheumatoid arthritisTheo S Plantinga, Jaap Fransen, Nozomi Takahashi, et al.
Rheumatology (Oxford, England)|August 24, 2016
An easy prediction rule for diffuse cutaneous systemic sclerosis using only the timing and type of first symptoms and auto-antibodies: derivation and validationWieneke M T van den Hombergh, Patricia E Carreira, Hanneke K A Knaapen-Hans, et al.
Clinical and Experimental Rheumatology|April 7, 2016
A multidimensional 'path analysis' model of factors explaining fatigue in rheumatoid arthritisSanne A A Rongen-van Dartel, Han Repping-Wuts, Rogier Donders, et al.
Clinical and Experimental Rheumatology|August 29, 2015
(Bi)Weekly folic acid supplementation might be inferior to a daily folic acid dosing schedule in the prevention of methotrexate-related toxicity in patients with rheumatoid arthritisBartholomeus J F van den Bemt, Alfons A den Broeder, Marielle Van der Burgt, et al.
Pageof 11

Showing results (51-60 of 108) with videos related to

Sort By:
Pageof 11
Pharmacogenomics|January 11, 2019
Validation of a clinical pharmacogenetic model to predict methotrexate nonresponse in rheumatoid arthritis patientsFrank Eektimmerman, Cornelia F Allaart, Johanna M Hazes, et al.
Annals of the Rheumatic Diseases|November 14, 2009
Limited validity of the American College of Rheumatology criteria for classifying patients with gout in primary careHein J E M Janssens, Mathijs Janssen, Eloy H van de Lisdonk, et al.
Clinical and Experimental Rheumatology|August 6, 2013
A comparison of the measurement properties and estimation of minimal important differences of the EQ-5D and SF-6D utility measures in patients with systemic sclerosisLinda Kwakkenbos, Jaap Fransen, Madelon C Vonk, et al.
The Journal of Rheumatology|March 3, 2010
Multiplex screening of 22 single-nucleotide polymorphisms in 7 Toll-like receptors: an association study in rheumatoid arthritisChristian Enevold, Timothy R D Radstake, Marieke J H Coenen, et al.
Rheumatology (Oxford, England)|August 14, 2016
Survival and organ involvement in patients with limited cutaneous systemic sclerosis and anti-topoisomerase-I antibodies: determined by skin subtype or auto-antibody subtype? A long-term follow-up studyPim Kranenburg, Wieneke M T van den Hombergh, Hanneke K A Knaapen-Hans, et al.
Pharmacogenomics|July 31, 2012
Clinical pharmacogenetic model to predict response of MTX monotherapy in patients with established rheumatoid arthritis after DMARD failureJaap Fransen, Wouter M Kooloos, Judith A M Wessels, et al.
Arthritis Research & Therapy|February 18, 2010
Functional consequences of DECTIN-1 early stop codon polymorphism Y238X in rheumatoid arthritisTheo S Plantinga, Jaap Fransen, Nozomi Takahashi, et al.
Rheumatology (Oxford, England)|August 24, 2016
An easy prediction rule for diffuse cutaneous systemic sclerosis using only the timing and type of first symptoms and auto-antibodies: derivation and validationWieneke M T van den Hombergh, Patricia E Carreira, Hanneke K A Knaapen-Hans, et al.
Clinical and Experimental Rheumatology|April 7, 2016
A multidimensional 'path analysis' model of factors explaining fatigue in rheumatoid arthritisSanne A A Rongen-van Dartel, Han Repping-Wuts, Rogier Donders, et al.
Clinical and Experimental Rheumatology|August 29, 2015
(Bi)Weekly folic acid supplementation might be inferior to a daily folic acid dosing schedule in the prevention of methotrexate-related toxicity in patients with rheumatoid arthritisBartholomeus J F van den Bemt, Alfons A den Broeder, Marielle Van der Burgt, et al.
Pageof 11